Geode Capital Management LLC Has $3.64 Billion Position in Gilead Sciences, Inc. $GILD

Geode Capital Management LLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 29,696,002 shares of the biopharmaceutical company’s stock after selling 232,984 shares during the quarter. Geode Capital Management LLC’s holdings in Gilead Sciences were worth $3,637,369,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $28,000. Financial Consulate Inc. grew its holdings in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. grew its holdings in Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 86 shares during the period. BOCHK Asset Management Ltd acquired a new stake in Gilead Sciences during the 4th quarter worth about $31,000. Finally, MTM Investment Management LLC grew its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares in the company, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 63,000 shares of company stock valued at $8,523,570. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Mizuho increased their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Argus increased their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Jefferies Financial Group began coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. Finally, Truist Financial reissued a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Price Performance

GILD stock opened at $133.69 on Thursday. The stock has a market capitalization of $165.99 billion, a PE ratio of 18.21 and a beta of 0.31. The company’s 50-day moving average is $135.60 and its 200-day moving average is $133.96. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.